In exploratory multivariate analysis, Pembrolizumab treatment showed a numerical trend toward improved survival compared to other PD-1 inhibitors.
← all excerpts
Modulation of the tumor immune microenvironment by Interferon Regulatory Factor 8 enhances immunotherapy in lung adenocarcinoma.
1
—
—